Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of the New Drug Application (NDA) for Oclaiz™ (CAM2029), ...
Happy New Year! If you’ve been sleeping on AI companion chatbot regulation, it’s time to wake up. As of January 1, 2026, California’s Senate Bill 243 is in effect, and unlike prior bot disclosure laws ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback